Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Incidence of prostate and urological cancers in England by ethnic group, 2001-2007: a descriptive study

  • Mahiben Maruthappu1,
  • Isobel Barnes2,
  • Shameq Sayeed2 and
  • Raghib Ali2, 3Email author
BMC Cancer201515:753

https://doi.org/10.1186/s12885-015-1771-2

Received: 17 February 2015

Accepted: 10 October 2015

Published: 21 October 2015

Abstract

Background

The aetiology of urological cancers is poorly understood and variations in incidence by ethnic group may provide insights into the relative importance of genetic and environmental risk factors. Our objective was to compare the incidence of four urological cancers (kidney, bladder, prostate and testicular) among six non-White ethnic groups in England (Indian, Pakistani, Bangladeshi, Black African, Black Caribbean and Chinese) to each other and to Whites.

Methods

We obtained Information on ethnicity for all urological cancer registrations from 2001 to 2007 (n = 329,524) by linkage to the Hospital Episodes Statistics database. We calculated incidence rate ratios adjusted for age, sex and income, comparing the six ethnic groups (and combined South Asian and Black groups) to Whites and to each other.

Results

There were significant differences in the incidence of all four cancers between the ethnic groups (all p < 0.001). In general, ‘non-White’ groups had a lower incidence of urological cancers compared to Whites, except prostate cancer, which displayed a higher incidence in Blacks. (IRR 2.55) There was strong evidence of differences in risk between Indians, Pakistanis and Bangladeshis for kidney, bladder and prostate cancer (p < 0.001), and between Black Africans and Black Caribbeans for all four cancers (p < 0.001).

Conclusions

The risk of urological cancers in England varies greatly by ethnicity, including within groups that have traditionally been analysed together (South Asians and Blacks). In general, these differences are not readily explained by known risk factors, although the very high incidence of prostate cancer in both black Africans and Caribbeans suggests increased genetic susceptibility. g.

Keywords

Urological Cancer Ethnic Prostate Incidence Kidney Bladder Testicular

Background

Urological cancers account for about 14 % of cancers diagnosed globally and more than a fifth of all cancers in Europe [1]. There is also significant international variation in incidence and the aetiology of urological cancers remains poorly understood. Identifying the extent of ethnic variation can contribute to our understanding of aetiology and assist in planning care for different ethnic groups. Unfortunately international comparisons are of limited value as registration systems vary in their quality; there are systematic variations between health systems and systematic biases exist in the way different populations access care [2].

The UK is a multi-ethnic society, with ‘non-White’ ethnic groups making up around 14 % of England's population in 2011. British (South) Asians - Indians, Pakistanis and Bangladeshis—form the largest group of about 6 %, and British Blacks - Black Africans (mainly from Nigeria, South Africa, Ghana and Somalia) and Black Caribbeans (predominantly from Jamaica)—are second at about 3 %, with Chinese (mainly from Hong Kong) about 1 % [3]. Studies have shown South Asians in the U.S. to have lower rates of kidney, bladder, prostate and testicular cancer than Whites and Blacks [4]. South Asians, however, are a heterogeneous group with varied socio-cultural practices and the risk of urological cancers within each individual ethnic group is unknown. Further, these data do not consider socioeconomic status, and are therefore subject to under-reporting in ethnic groups with decreased access to care [5].

Although it has long been known that there are differences in the incidence of many cancers by ethnic group [6] and in access to healthcare (including screening) due to socioeconomic disadvantages [7], studies of cancer incidence in ethnic groups in the UK have been of limited accuracy in the past due to the incomplete ethnicity data held by cancer registries. Various techniques have been used to try and overcome this problem, including using country of birth, the calculation of proportional incidence ratios and assigning ethnicity on the basis of name [810]. However, all these methods have significant limitations and the most accurate method is to use self–assigned ethnicity (as has been done in the census since 1991) which allows us to use the same method of assigning ethnicity in the numerator and denominator.

From 1995, self-assigned ethnicity has been recorded in the National Health System’s Hospital Episodes Statistics (HES) database, and HES records can now be linked to cancer registrations, providing more reliable information on ethnicity [11]. Although the recording of routine ethnicity data in primary care is still limited [12], hospital data is much better and has improved markedly in the last 20 years, with the percentage of missing ethnicity values falling from 35 % in 1998 to less than 10 % by 2009 [13]. In England, consistency of diagnostic methods, reporting and registration procedures across the entire health system removes significant biases intrinsic to databases in many other countries.

Our objective was to compare the incidence of kidney, bladder, prostate and testicular cancer amongst ethnic groups (Indian, Pakistani, Bangladeshi, Black African, Black Caribbean and Chinese) in England, to each other and to Whites.

Methods

The methods used in this study were broadly the same as those described in our previous studies [1416] and are summarized below.

Data collection

Data were obtained from the National Cancer Intelligence Network (NCIN) for all cancer registrations from January 2001 to December 2007 in England: cancer site coded to the International Classifications of Diseases, 10th Revision (ICD-10) [17]; morphology coded to the International Classifications of Diseases of Oncology, 2nd and 3rd Revisions (ICD-O-2 and ICD-O-3) [18, 19]; deprivation assessed from the income domain of the Index of Multiple Deprivation 2007 (IMD 2007) [20]; age at diagnosis of cancer; sex and ethnicity. To determine population incidence data, mid-year population estimates produced by the Office of National Statistics (ONS) from 2001 to 2007 were used, stratified by age, sex and ethnicity. Population data stratified by national quintiles of the income domain were provided by ONS based on the 2001 census and the same distributions applied to population data by age, sex and ethnicity for the 2001-2007 mid-year population estimates.

Classification of ethnicity

NCIN obtained the self-assigned ethnicity for each cancer registration by record linkage to the Hospital Episodes Statistics (HES) database. If a cancer registration could not be linked to HES, or if ethnicity data were missing on the HES database, then ethnicity was assigned using information recorded in the cancer registry data. Prior to April 2001, ethnicity was coded both by HES and by cancer registries using the classification system of the 1991 Census. After April 2001, the codes were amended to those of the 2001 Census, although 1991 ethnicity codes were accepted until 2003. For these analyses, we classified ethnicity as White (White from the 1991 Census and White British from the 2001 Census), Indian, Pakistani and Bangladeshi, (with the three groups combined to form the category ‘South Asian’), Black African, Black Caribbean (again both combined to form the category, ‘Black’) and Chinese. (Sri Lankans are not recorded as a separate ethnic group in the census or HES data and so are not included in our analysis.)

Classification of cancers

Cancers were classified as cancers of the prostate (ICD-10 code C61), testes (C62), kidney (C64, C65, C66 and C68) and bladder (C67).

Statistical analyses

We estimated age standardised rates (ASRs) of each cancer per 100,000 person-years for all ethnic groups using direct standardisation to the 1960 Segi world population [21], with age at diagnosis of cancer being classified into 6 categories: <40, 40–49, 50–59, 60–69, 70–79, and ≥ 80 years. We used Poisson regression to estimate incidence rate ratios (IRRs) comparing each ethnic group, and the two combined categories of South Asian and Black, to Whites adjusting for age, sex (where appropriate) and deprivation.

When comparing South Asians and Blacks to Whites, we present results as RRs and 99 % confidence intervals (CIs). When comparing the individual ethnic groups, results are presented as IRRs and 99 % floating confidence intervals (FCIs). FCIs were calculated using the method of floating absolute risks [22] and enable valid comparisons between any two ethnic groups, even if neither one is the baseline. We calculated 99 % CIs because of multiple tests performed across ethnic groups.

We performed pre-specified subgroup analyses by sex, where appropriate, and by tumor type, which were grouped according to morphology. Specifically cancers of the prostate were grouped as adenocarcinoma (ICD-O-3 codes 8140, 8141 8143, 8147, 8211, 8251, 8255, 8260–82633, 8310, 8480, 8481, 8503, 8570–8574) and other tumors; cancer of the testes as seminoma (9060–9062, 9064) and non-seminomatous (9065–9102); cancer of the kidney as renal cell carcinoma (8050, 8140,8260, 8270, 8280–8312, 8316–8320, 8340–8344) and other; and cancer of the bladder as transitional (8050,8120–8122,8130–8131) and other. We also did a pre-specified subgroup analysis by age for prostate cancer, with cases divided into those aged under 50 and those aged 50 or above. We did not analyse the other cancers by age as case numbers were too low.

Tests of heterogeneity of IRRs between ethnicities, either overall or restricted to South Asians or Blacks, were performed using likelihood χ2 ratio tests. The test of heterogeneity of RRs between pre-specified subgroups was performed for South Asians, Blacks and Chinese using a χ2 contrast test.

Sensitivity analysis

Because ethnicity information was not complete for all registered cancers, we used multiple imputations to assess the effect the missing values of ethnicity had on our results. We generated 40 datasets with imputed values of ethnicity using a multinomial logistic regression model where the predictor variables were age, deprivation (income) and site of cancer. We performed our primary analysis examining the effect of ethnicity on cancer for each dataset. The resulting IRRs were combined using Rubin’s combination rules [23].

We performed all analyses using Stata V.12 and R statistical software packages.

Graphical presentation of results

Where results are presented in the form of plots, we represent IRRs for each ethnic group by squares and their corresponding 99 % FCIs by straight lines. For the combined ‘South Asian’ and ‘Black’ group, we show IRRs as open diamonds, whose horizontal extent indicates the 99 % CI. We placed a dashed vertical line at the value of the IRRs for all South Asians and for all Blacks.

Comparison to rates in countries of origin

We also compared the ASRs for each ethnic group in England to rates from their country or region of origin using data from the GLOBOCAN database [1]. For Blacks, we used GLOBOCAN estimates for Sub-Saharan Africa and the Caribbean; there are no population based cancer registries in their main countries of origin.

This study was approved by the Oxford Research Ethics Committee.

Results

Table 1 shows socio-demographic information from the 2001 census for Whites, Indians, Pakistanis, Bangladeshis, Black Africans, Black Caribbeans and Chinese. All six groups are, on average, younger than Whites and all except Chinese are also poorer, with Pakistanis, Bangladeshis and Black Africans being the most deprived.
Table 1

Comparison of demographic characteristics by ethnic group in England in 2001 using data from the 2001 census

Ethnic group

White

Indian

Pakistani

Bangladeshi

Black African

Black Carribean

Chinese

  

N

(%)

N

(%)

N

(%)

N

(%)

N

(%)

N

(%)

N

(%)

Census data for 2001

              

Total population

 

42,747,136

100

1,028,546

100

706,539

100

275,394

100

475,938

100

561,246

100

220,681

100

Sex

Male

20,828,644

48.7

511,204

49.7

358,043

50.7

138,972

50.5

229,103

48.1

259,881

46.3

105,913

48.0

Age

<50

27,665,393

64.7

828,200

80.5

625,118

88.5

248,841

90.4

432,985

91.0

426,424

76.0

184,675

83.7

50+

15,081,743

35.3

200,346

19.5

81,421

11.5

26,553

9.6

42,953

9.0

134,822

24.0

36,006

16.3

Deprivation

Low income

7,305,527

17.1

347,098

33.7

455,710

64.5

198,884

72.2

277,858

58.4

292,537

52.1

49,427

22.4

Middle income

26,315,786

61.6

563,939

54.8

222,038

31.4

69,325

25.2

177,234

37.2

245,103

43.7

123,994

56.2

High income

9,125,823

21.3

117,509

11.4

28,791

4.1

7,185

2.6

20,846

4.4

23,606

4.2

47,260

21.4

Country of Birth

United Kingdom

41,911,150

98.0

472,545

45.9

387,198

54.8

127,902

46.4

161,050

33.8

324,764

57.9

62,209

28.2

Other

835,986

2.0

556,001

54.1

319,341

45.2

147,492

53.6

314,888

66.2

236,482

42.1

158,472

71.8

Table 2 shows the number of cancer registrations by ethnic group, and missing ethnicity values for each cancer. In total there were 329,524 urological cancer registrations and ethnicity information was missing in 81,767 (24.8 %) cases.
Table 2

Distribution of registered cancers from 2001-2007 in England by ethnic group and missing ethnicity values (percentages in brackets)

Cancer

White

Indian

Pakistani

Bangladeshi

Black African

Black Caribbean

Chinese

All other ethnic groups

No ethnicity recorded

Total

Prostate

132278

(62.5)

934

(0.4)

491

(0.2)

90

(0.0)

861

(0.4)

3185

(1.5)

226

(0.1)

10624

(5.0)

63068

(29.8)

211757

Testes

50133

(81.2)

223

(0.4)

117

(0.2)

42

(0.1)

69

(0.1)

186

(0.3)

62

(0.1)

3135

(5.1)

7762

(12.6)

61729

Kidney

7890

(65.7)

88

(0.7)

65

(0.5)

8

(0.1)

17

(0.1)

28

(0.2)

18

(0.2)

831

(6.9)

3064

(25.5)

12009

Bladder

32775

(74.4)

246

(0.6)

170

(0.4)

58

(0.1)

146

(0.3)

239

(0.5)

57

(0.1)

2465

(5.6)

7873

(17.9)

44029

All four cancers

223076

(67.7)

1491

(0.5)

843

(0.3)

198

(0.1)

1093

(0.3)

3638

(1.1)

363

(0.1)

17055

(5.2)

81767

(24.8)

329524

Figure 1 shows the overall age-standardised incidence rates and rate ratios, adjusted by age, sex and income, for the four urological cancers by individual ethnic group compared to Whites. For all four cancers, there is significant heterogeneity between ethnic groups (p < 0.001), with a lower incidence for all ethnic groups compared to Whites, for all cancers except prostate cancer, where Blacks had by far the highest incidence.
Fig. 1

Age-standardised incidence rates and rate ratios (adjusted by age, sex and income) for the four urological cancers by individual ethnic group compared to Whites

For kidney cancer (Fig. 2), the overall incidence in Chinese and South Asians was about half that in Whites, with risk in Indians significantly lower than in Pakistanis and Bangladeshis. (IRRs of 0.47, 0.67 and 0.66 respectively, P < 0.001). The incidence in Blacks was also lower than Whites with higher rates in Black Africans than Black Caribbeans. (IRRs of 0.94 and 0.67 respectively, P = 0.002). These trends were maintained in subgroup analyses by tumour type. Across all ethnicities, risk was higher in men than women but the relative risk compared to Whites was similar in men and women for all non-White groups.
Fig. 2

Age-standardised incidence rates and rate ratios (adjusted by age and income) for prostate cancer by ethnic group. Subgroups show rates and rate ratios subdivided by age and morphology (adenocarcinoma and other)

For bladder cancer (Fig. 3), the overall incidence in South Asians and Blacks was nearly two thirds lower than in Whites with no significant difference between Indians, Pakistanis and Bangladeshis, or between Black Africans and Black Caribbeans. The risk in Chinese was about half that of Whites. These trends were maintained in subgroup analyses by tumour type. Across all ethnicities, risk was higher in men than women but the relative risk compared to Whites was similar in men and women for all non-White groups.
Fig. 3

Age-standardised incidence rates and rate ratios (adjusted by age and income) for testicular cancer by ethnic group. Subgroups show rates and rate ratios subdivided by morphology (seminoma and non-seminomatous)

For prostate cancer (Fig. 4), the overall incidence in South Asians was almost half that in Whites with substantial differences between Indians, Pakistanis and Bangladeshis (IRRs of 0.55, 0.64 and 0.33 respectively, P < 0.001) with Chinese also having a lower incidence than Whites. The incidence in both Black Caribbeans and Black Africans was more than double that of Whites. These trends were confirmed in subgroup analyses by both age and tumour type; Black Caribbeans and Black Africans displayed the highest incidence in both those aged less than and greater than 50 and in both adenocarcinoma and ‘other’ types of prostate cancer.
Fig. 4

Age-standardised incidence rates and rate ratios (adjusted by age, sex and income) for kidney cancer by ethnic group. Subgroups show rates and rate ratios subdivided by sex and morphology (renal cell cancer & other)

For testicular cancer (Fig. 5), incidence in all ethnic groups was much lower than in Whites, about a third in South Asians and Chinese with blacks having the lowest incidence and lower rates in Black Africans than Black Caribbeans. These trends were maintained in subgroup analyses by tumour type and also showed that South Asians have a higher incidence of non-seminomatous tumours compared to seminomas.
Fig. 5

Age-standardised incidence rates and rate ratios (adjusted by age, sex and income) for bladder cancer by ethnic group. Subgroups show rates and rate ratios subdivided by sex and by morphology (transitional cell cancer & other)

Sensitivity analysis

In the sensitivity analysis which assigned missing values using multiple imputations, results very similar to those shown in Fig. 1 were obtained, as shown in Additional file 1: figure S1 (online).

Comparison to rates in countries of origins

Table 3 compares international data on age standardised incidence rates from GLOBOCAN. Across all ethnicities, ASRs for kidney, prostate and testicular cancers were lower in their countries of origins. Bladder cancer incidence was higher in respective countries of origins, than in comparative ethnicities in England. For all ethnicities, in both England and countries of origins, the incidence of kidney, bladder, prostate and testicular cancers was less than in Whites, except for prostate cancer in Caribbeans which was higher in the Carribean than in Whites.
Table 3

Age-standardised incidence rates for urological cancers by ethnic group in England compared to rates in country of origin using estimates from Globocan. (sub-Saharan Africa for Black Africans, Caribbean for Black Caribbeans)

  

England

Incidence from Globocan

Cancer Site

Ethnicity

Cases

ASR

ASR

Prostate

White

132278

44.9

 
 

Indian

934

23.7

3.7

 

Pakistani

491

26.2

5.2

 

Bangladeshi

90

14.0

1.9

 

Black African

861

99.2

21.2

 

Black Caribbean

3185

110.1

71.1

 

Chinese

226

34.6

4.3

Testes

White

50133

11.6

 
 

Indian

223

6.8

0.6

 

Pakistani

117

9.5

0.9

 

Bangladeshi

42

6.3

1.0

 

Black African

69

8.9

0.4

 

Black Caribbean

186

6.4

0.7

 

Chinese

62

9.8

0.4

Kidney

White

7890

5.9

 
 

Indian

88

3.0

1.1

 

Pakistani

65

4.3

1.3

 

Bangladeshi

8

4.2

1.1

 

Black African

17

5.5

1.1

 

Black Caribbean

28

4.5

2.7

 

Chinese

18

3.4

2.8

Bladder

White

32775

7.2

 
 

Indian

246

2.7

2.8

 

Pakistani

170

3.2

5.4

 

Bangladeshi

58

3.7

2.6

 

Black African

146

3.6

3.7

 

Black Caribbean

239

3.1

5.8

 

Chinese

57

3.9

5.5

Discussion

We compared incidence rates for urological cancers in the main ‘non-White’ ethnic groups in England – South Asian (Indian, Pakistani and Bangladeshi), Black (African and Caribbean) and Chinese to Whites and to each other. There was considerable variation by ethnic group, even when age and socioeconomic factors were taken into account. Overall, urological cancers were diagnosed less often in all the ‘non-White’ ethnic groups, except prostate cancer in Blacks, which demonstrated a higher incidence than in Whites. Amongst South Asians, we demonstrated that the incidence of urological cancers substantially differed between Pakistanis, Bangladeshis and Indians, supporting the notion that South Asians should not be viewed as a single ethnic group. Similarly, large differences existed between Black African and Caribbean populations, highlighting the need to differentiate between these two groups.

The different patterns of cancer risk between ethnic groups suggest that our findings are unlikely to be due to systematic reporting biases in any of the ethnic groups compared to Whites. Our previous work using the same dataset showed increased risks of some gastrointestinal and haematological cancers in ethnic minority groups further supporting the absence of an under-reporting bias [14, 15]. Using self-assigned ethnicity is also more reliable than other measures of ethnicity (e.g. name analysis) as it uses the same measure of ethnicity in the numerator and denominator. We also adjusted for socioeconomic status, a potential confounder in studies of health and ethnicity, particularly when comparing Pakistanis, Bangladeshis and Blacks due to their higher levels of deprivation [5].

Our findings are consistent with current literature although we are not aware of any previous studies which present incidence by individual ethnic group for kidney, bladder and testes cancers. (which grouped all ‘Blacks’ and all ‘South Asians’ together.)

For renal cancer, a previous study showed that South Asians had a lower incidence of renal cell carcinoma compared with Whites, consistent with our results [24]. Smoking is a known risk factor for renal cell carcinoma [25] and our results are consistent with smoking prevalence by ethnic group [26]. Some reports have demonstrated higher incidence of renal cell carcinoma in African Americans than Whites [27], contrary to our findings. This discrepancy may be attributable to the fact that these studies were done in the USA where black populations may have different countries of origin.

For bladder cancer, previous reports indicate a lower incidence amongst south Asians [28]. Again, smoking is a known risk factor for bladder cancer [29] and our results are consistent with smoking prevalence by ethnic group with the exception of Chinese [26] who have the lowest smoking prevalence but the highest bladder cancer incidence. This may be due to genetic factors or other ethnicity-specific risk factors (e.g. dietary soy) which is frequently used in Chinese cuisine, has been associated with increased bladder cancer risk [30].

For testicular cancer, previous studies have also revealed a lower incidence amongst Asians and Blacks [31] consistent with our data. This may be due to inter-ethnic variations in environmental factors acting prenatally or early in childhood [32]. Cryptorchidism, a known risk factor of testicular cancer, may also vary between ethnicities, with reports of reduced incidence amongst black babies [33] but data is not available for South Asians.

For prostate cancer, studies in the USA have shown increased incidence in men with African ancestry, even after migration to areas of lower prevalence [34, 35]. Our finding that Black African and Black Caribbean’s demonstrated a higher incidence of prostate cancer than Whites is also consistent with previous UK studies [28, 31].

The specific cause of increased prostate cancer risk amongst Blacks is not known. A recent review of known risk factors for prostate cancer found limited environmental explanation for the racial differences in incidence [36]. Nonetheless, there have been a number of dietary factors which have been independently implicated, including intake of animal fats and products [37]. Increased risk amongst Blacks has also been attributed to genetic factors including: variants of the genes of the enzymes involved in androgen biosynthesis and metabolism, such as SRD5A2, CYP17, and CYP3A4; the C-genotypes CD14; NAT2 and NER genetic variants; and polymorphisms at 17q21 and 8q24 [3842]. Although the much higher rates seen in Black Africans and Caribbean in the UK compared to their regions of origin is consistent with a change of environment causing the increase, the very low rates seen in sub-saharan Africa almost certainly underestimate the true incidence due to under-diagnosis and under-reporting. We also note that rates are generally higher in black populations everywhere—sub-Saharan Africa and the Caribbean, (where they are almost double compared to other similarly developed regions) [1], Blacks in the US and Blacks in the UK. This suggests that the increased risk seen in Blacks in the UK is most likely due to the change in environment in genetically susceptible populations.

The role of genetics in determining variation in risk is reinforced by the observation that both black Africans and Caribbeans display increased prostate cancer incidence, despite different countries of origin; lifestyles and environments.

Consistent with our findings, previous reports have also demonstrated reduced prostate cancer incidence in Asians compared with Whites [28], and within the subset of Asians: Indians, Pakistanis and Bangladeshis [4347]. The reduced incidence amongst South Asians has been associated with religion, differences in diet, reduced vitamin D levels and early-life sun exposure [48, 49]. Other risk factors associated with prostate cancer are lack of exercise, antioxidants and saturated fat, smoking, alcohol consumption, socioeconomic status and carcinogen exposure (e.g. radiation and arsenic) [5053] and it is possible that differences in these explain some of the reduced incidence in South Asians. Further, it has been suggested that South Asians meet with more obstacles when accessing health care resources, receiving less diagnostic and screening (PSA) tests [54]. Within South Asian ethnic groups, Bangladeshis displayed a substantially lower incidence of prostate cancer; although the cause of this is likely multifactorial, obesity has been linked to prostate cancer [55], and Bangladeshis show markedly lower obesity prevalence compared to Indians and Pakistanis [26]. Prostate cancer incidence in Chinese was higher than in South Asians and this may in part be contributed to by increased soy, genistein and daidzein intake [56].

The comparison of rates between ethnic groups in England and their countries of origin is problematic for a number of reasons. Firstly, population-based cancer registries simply do not exist in many of these countries, particularly in the areas from where the majority of migrants originate e.g. Punjab & Gujarat in India, Kashmir & Punjab in Pakistan, Sylhet in Bangladesh, Jamaica in the Caribbean and Somalia, Nigeria & Ghana in Africa. and Even where registries exist the quality is very variable and there are differences in cancer registration practices [2]. Rates in these developing countries are also likely to be underestimated due to under-diagnosis and under-ascertainment, and in access to screening and early detection, particularly for prostate cancer [2]. Migrants are also a selective group and may not be representative of the population from which they arose and they may be more or less healthy than the population in their native country [6].

Whilst acknowledging these limitations, the increased incidence of prostate, kidney and testicular cancers in all ethnic groups in England compared to their countries of origin is consistent with changes in environmental risk factors and the differences in screening, diagnosis and registration. For bladder cancer the picture was more mixed with higher incidence seen in the countries of origin of Pakistanis, Black Caribbean and Chinese—the reasons for this are unclear.

The main limitation of our study was that we do not have individual level information on most exposures. Ethnicity information was missing for 25 % of cancer registrations—however, this is lower than previous studies [28, 44] and the sensitivity analysis produced similar results. Recording of ethnicity in HES has improved markedly in the last 20 years, with the percentage of missing ethnicity values falling from 35 % in 1998 to less than 10 % by 2009. The quality of the ethnic coding in HES has also been assessed and no ethnic group is widely misrepresented in HES data for England [13, 14].

Also, the group ‘British White’ inevitably included some ‘Other (non-British) Whites’ as the ethnic category ‘Whites’ included both British Whites and ‘Other Whites’ prior to 2003 although this was less than 5 % of the ‘total White’ category based on the data post-2003 so would not materially affect the results for British Whites. We were therefore also unable to compare British Whites to ‘Other Whites’, and given that the ‘Other White’ population has increased rapidly since 2004 (due to migration from the European Union), future studies should look at incidence in this group as well.

Conclusions

This is the first and largest study to investigate the differences in incidence of urological cancers by ethnic group in England. The very high incidence of prostate cancer in both black Africans and Caribbeans, despite differing lifestyles and environments and countries of origin is most likely due to the change in environment in genetically susceptible populations. The large differences in incidence we found with other cancers by ethnic group are not readily explained by known risk factors, which suggest that important, potentially modifiable, risk factors are yet to be discovered.

Abbreviations

HES: 

Hospital Episodes Statistics

NCIN: 

National Cancer Intelligence Network

ICD-10: 

International Classifications of Diseases, 10th Revision

ICD-O-2: 

International Classifications of Diseases of Oncology, 2nd Revision

ICD-O-3: 

International Classifications of Diseases of Oncology, 3rd Revision

ASRs: 

Age Standardised Rates

IRRs: 

Incidence Rate Ratios

Declarations

Acknowledgments

We thank the National Cancer Intelligence Network (NCIN) and the Office for National Statistics (ONS) for providing the data.

Funding

RA and IB are employed by the Cancer Epidemiology Unit at the University of Oxford which is supported by Cancer Research UK. The sponsor of the study had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Green Templeton College, University of Oxford
(2)
Cancer Epidemiology Unit, University of Oxford
(3)
New York University Abu Dhabi

References

  1. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, F. Bray (2014). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer doi:https://doi.org/10.1002/ijc.29210 PMID:25220842 Published online 9 October 2014.
  2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi:https://doi.org/10.1002/ijc.29210. Epub 2014 Oct 9.View ArticlePubMedGoogle Scholar
  3. Office for National Statistics. Ethnicity and National Identity in England and Wales 2011. London: Office for National Statistics; 2012. Available at: http://www.ons.gov.uk/ons/rel/census/2011-census/key-statistics-for-local-authorities-in-england-and-wales/rpt-ethnicity.html.Google Scholar
  4. Hossain A, Hogan TF, Rahman R, Hobbs G. Survival Disparities in Bladder, Kidney, and Prostate Cancer in Asian-Indian & Pakistani Immigrants to the United States as Compared to Other US Ethnic Groups: A Surveillance, Epidemiology and End Result (SEER) 2011 Public Use Database Study. Cancer Clin Oncol. 2013;2(1).Google Scholar
  5. Udayaraj U, Ben-Shlomo Y, Roderick P, Casula A, Dudley C, Johnson R, et al. Social deprivation, ethnicity, and access to the deceased donor kidney transplant waiting list in England and Wales. Transplantation. 2010;90(3):279–85.View ArticlePubMedGoogle Scholar
  6. Parkin DM, Khlat M. Studies of cancer in migrants: rationale and methodology. Eur J Cancer. 1996;32A(5):761–71.View ArticlePubMedGoogle Scholar
  7. Morris M, Woods LM, Rogers N, O’Sullivan E, Kearins O, Rachet B. Ethnicity, deprivation and screening: survival from breast cancer among screening-eligible women in the West Midlands diagnosed from 1989 to 2011. Br J Cancer. 2015;113(3):548–55.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Winter H, Cheng KK, Cummins C, Maric R, Silcocks P, Varghese C. Cancer incidence in the south Asian population of England (1990-92). Br J Cancer. 1999;79(3-4):645–54.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Smith LK, Peake MD, Botha JL. Recent changes in lung cancer incidence for south Asians: a population based register study. BMJ. 2003;326(7380):81–2.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, et al. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol. 2008;37(1):147–60.View ArticlePubMedGoogle Scholar
  11. Ethnic group statistics: a guide for the collection and classification of ethnicity data.: Office for National Statistics. 2003 http://www.ons.gov.uk/ons/guide-method/measuring-equality/equality/measuring-equality--a-guide/ethnicgroup-statistics--a-guide-for-the-collection-and-classification-of-ethnicity-data.pdf.
  12. Mathur R, Bhaskaran K, Chaturvedi N, Leon DA, VanStaa T, Grundy E, et al. Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health (Oxf). 2014;36(4):684–92.View ArticleGoogle Scholar
  13. The NHS Information Centre. How good is HES ethnic coding and where do the problems lie? 2011http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=171.
  14. Ali R, Barnes I, Cairns BJ, Finlayson AE, Bhala N, Mallath M, et al. Incidence of gastrointestinal cancers by ethnic group in England, 2001-2007. Gut. 2012;62:1692–703.View ArticlePubMedGoogle Scholar
  15. Shirley MH, Sayeed S, Barnes I, Finlayson A, Ali R. Incidence of haematological malignancies by ethnic group in England, 2001-7. Br J Haematol. 2013;163(4):465–77.View ArticlePubMedGoogle Scholar
  16. Shirley MH, Barnes I, Sayeed S, Finlayson A, Ali R. Incidence of breast and gynaecological cancers by ethnic group in England, 2001-2007: a descriptive study. BMC Cancer. 2014;14:979. doi:https://doi.org/10.1186/1471-2407-14-979.View ArticlePubMedPubMed CentralGoogle Scholar
  17. World Health Organization. International Statistical Classification of Diseases and Related Health Outcomes , 10th Revision. Geneva: World Health Organization; 1992.Google Scholar
  18. World Health Organization. International Classification of Diseases for Oncology, 3rd Revision. Geneva: World Health Organization; 2000.Google Scholar
  19. World Health Organization. International Classification for Diseases of Oncology, 2nd Revision. Geneva: World Health Organization; 1990.Google Scholar
  20. Noble M, McLennan D, Wilkinson K, Whitworth A, Barnes H, Dibben C. The English Indices of Deprivation 2007. London: Communities and Local Government; 2008.Google Scholar
  21. Segi M. Cancer Mortality for Selected Sites in 24 Countries (1950-57). Sendai: Department of Public Health, Tohoku University of Medicine; 1960.Google Scholar
  22. Easton DF, Peto J, Babiker AG. Floating absolute risk - an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med. 1991;10:1025–35.View ArticlePubMedGoogle Scholar
  23. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.View ArticleGoogle Scholar
  24. Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol. 2008;179(5):1704–8.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005;114:101–8.View ArticlePubMedGoogle Scholar
  26. Sproston K, Mindell J. Health Survey for England 2004. The health of minority ethnic groups. London: The Stationery Office; 2006.Google Scholar
  27. Lipworth L, McLaughlin JK, Tarone RE, Blot WJ. Renal cancer paradox: higher incidence but not higher mortality among African-Americans. Eur J Cancer Prev. 2011;20(4):331–3.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Forman D. Cancer Incidence and Survival by Major Ethnic Group, England, 2002–2006. London: National Cancer Intelligence Network; 2009.Google Scholar
  29. Morrison AS, Buring JE, Verhoek WG, Aoki K, Leck I, Ohno Y, et al. An international study of smoking and bladder cancer. J Urol. 1984;131(4):650–4.PubMedGoogle Scholar
  30. Sun CL, Yuan JM, Arakawa K, Low SH, Lee HP, Yu MC. Dietary soy and increased risk of bladder cancer: the Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1674–7.PubMedGoogle Scholar
  31. Jack RH, Davies EA, Møller H. Testis and prostate cancer incidence in ethnic groups in South East England. Int J Androl. 2007;30(4):215–20.View ArticlePubMedGoogle Scholar
  32. Garner MJ, Turner MC, Ghadirian P, Krewski D. Epidemiology of testicular cancer: an overview. Int J Cancer. 2005;116:331–9.View ArticlePubMedGoogle Scholar
  33. McGlynn KA, Graubard BI, Klebanoff MA, Longnecker MP. Risk factors for cryptorchism among populations at differing risks of testicular cancer. Int J Epidemiol. 2006;35:787–95.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Merrill RM, Sloan A. Risk-adjusted incidence rates for prostate cancer in the United States. Prostate. 2012;72(2):181–5.View ArticlePubMedGoogle Scholar
  35. Wells TS, Bukowinski AT, Smith TC, Smith B, Dennis LK, Chu LK, et al. Racial differences in prostate cancer risk remain among US servicemen with equal access to care. Prostate. 2010;70(7):727–34.PubMedGoogle Scholar
  36. Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, et al. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur Urol. 2008;53(1):99–105.View ArticlePubMedGoogle Scholar
  37. Mordukhovich I, Reiter PL, Backes DM, Family L, McCullough LE, O’Brien KM, et al. A review of African American-white differences in risk factors for cancer: prostate cancer. Cancer causes control. 2011;22(3):341–57.View ArticlePubMedGoogle Scholar
  38. Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM, et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev. 1999;8(1):25–34.PubMedGoogle Scholar
  39. Hatcher D, Daniels G, Osman I, Lee P. Molecular mechanisms involving prostate cancer racial disparity. Am J Transl Res. 2009;1(3):235–48.PubMedPubMed CentralGoogle Scholar
  40. Mason TE, Ricks-Santi L, Chen W, Apprey V, Joykutty J, Ahaghotu C, et al. Association of CD14 variant with prostate cancer in African American men. Prostate. 2010;70(3):262–9.PubMedPubMed CentralGoogle Scholar
  41. Whitman EJ, Pomerantz M, Chen Y, Chamberlin MM, Furusato B, Gao C, et al. Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol Biomarkers Prev. 2010;19(1):1-8. doi: https://doi.org/10.1158/1055-9965.EPI-08-1111.
  42. Hooker S, Bonilla C, Akereyeni F, Ahaghotu C, Kittles RA. NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans. Prostate Cancer Prostatic Dis. 2008;11(4):349–56.View ArticlePubMedGoogle Scholar
  43. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet. 2011;43(6):570–3.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Jack RH, Davies EA, Møller H. Prostate cancer incidence, stage at diagnosis, treatment and survival in ethnic groups in South-East England. BJU Int. 2010;105(9):1226–30.View ArticlePubMedGoogle Scholar
  45. Metcalfe C, Patel B, Evans S, Ibrahim F, Anson K, Chinegwundoh F, et al. The risk of prostate cancer amongst South Asian men in southern England: the PROCESS cohort study. BJU Int. 2008;102(10):1407–12.PubMedGoogle Scholar
  46. Harding S, Rosato M. Cancer incidence among first generation Scottish, Irish, West Indian and South Asian migrants living in England and Wales. Ethn Health. 1999;4(1-2):83–92.View ArticlePubMedGoogle Scholar
  47. Wild SH, Fischbacher CM, Brock A, Griffiths C, Bhopal R. Mortality from all cancers and lung, colorectal, breast and prostate cancer by country of birth in England and Wales, 2001-2003. Br J Cancer. 2006;94(7):1079–85.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Maringe C, Mangtani P, Rachet B, Leon DA, Coleman MP, dos Santos SI. Cancer incidence in South Asian migrants to England, 1986-2004: unraveling ethnic from socioeconomic differentials. Int J Cancer. 2013;132(8):1886–94.View ArticlePubMedGoogle Scholar
  49. Hamson C, Goh L, Sheldon P, Samanta A. Comparative study of bone mineral density, calcium, and vitamin D status in the Gujarati and white populations of Leicester. Postgrad Med J. 2003;79:279–83.View ArticlePubMedPubMed CentralGoogle Scholar
  50. John EM, Koo J, Schwartz GG. Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. Cancer Epidemiol Biomarkers Prev. 2007;16:1283–6.View ArticlePubMedGoogle Scholar
  51. Chan J, Giovannucci E, Andersson S, Yuen J, Adami H, Wolk A. Dairy products, calcium, phosphorous, vitamin d, and risk of prostate cancer (Sweden). Cancer Causes Control. 1998;9(6):559–66.View ArticlePubMedGoogle Scholar
  52. Chan J, Stampfer M, Ma J, Gann P, Gaziano J, Giovannucci E. Dairy products, calcium, and prostate cancer risk in the physicians’ health study. Am J Clin Nutri. 2001;74(4):549–54.Google Scholar
  53. Peinta K, Esper P. Risk factors for prostate cancer. Ann Intern Med. 1993;118(10):793–803.View ArticleGoogle Scholar
  54. Bhopal R, Unwin N, White M, Yallop J, Walker L, Alberti KG et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ. 1999;319:215–20.View ArticlePubMedPubMed CentralGoogle Scholar
  55. Rundle A, Jankowski M, Kryvenko ON, Tang D, Rybicki BA. Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate. Cancer Epidemiol Biomarkers Prev. 2013;22(5):898–904.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 2003;12(7):665–8.PubMedGoogle Scholar

Copyright

© Maruthappu et al. 2015

Advertisement